Brief: Pds Biotech Announces Presentation Of Rationale And Design Of First Recurrent Prostate Cancer Trial To Combine An Androgen Receptor Pathway Inhibitor With An Immunocytokine
22/10/2024 14:37
Oct 22 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECH ANNOUNCES PRESENTATION OF RATIONALE AND DESIGN
OF
FIRST RECURRENT PROSTATE CANCER TRIAL TO COMBINE AN ANDROGEN
RECEPTOR PATHWAY INHIBITOR WITH AN IMMUNOCYTOKINE
Source text for Eikon: ID:nGNX1ml0mw
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing